Royalty Pharma Q2 adj cash receipts $545M (+4%); raises 2023 guidance to $2.9-2.975B

Royalty Pharma plc

2023-Q2 EPS reported $1.27 revenue$1,222,173,000

Net cash from ops $608M (+6% YoY); Adjusted Cash Receipts $545M (+4%), Adjusted EBITDA $498M (+4%).
Raised 2023 Adj Cash Receipts guidance to $2.900B-$2.975B from $2.85B-$2.95B, excluding new transactions.
YTD announced transactions up to $1.7B, including $659M upfront; began share repurchases.
CF franchise royalties +13% to $206M; Trelegy added $37M, Spinraza $13M; Imbruvica -22%, Xtandi -22%.
Adjusted Cash Flow $512M (+6%) driven by EBITDA growth and higher net interest received.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Royalty Pharma plc updated its the quarter ended June 30, 2023 guidance (raised).

Period: the quarter ended June 30, 2023
Guidance: raised
Result: reported results

Exact text from the filing

Royalty Pharma plc issued a press release announcing its financial results for the quarter ended June 30, 2023

View on SEC.gov

Browse all earnings releases →

Royalty Pharma plc filing history →

Source: SEC EDGAR

accession 0001802768-23-000022

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.